Dr. Jared Weiss sat down for an interview to discuss a trial evaluating JNJ-1900, an immune-stimulating radiation sensitizer, in those with lung cancer.

A patient and provider share updates on pelabresib plus Rituxan treatment, which met the MANIFEST-2 trial's primary end point ...

Christine Simonelli, B.S.N., RN, CCRC, OCN, is amazing, and goes out of her way to help patients and providers.

I want my family to understand our shared cancer risks, but I sometimes struggle to face the painful reality of the disease ...

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

The FDA has accepted and granted priority review to an NDA for sevabertinib in previously treated HER2+ non-small cell lung ...

Dr. Kristen Scarpato explains the role of genetic testing in prostate cancer care, as well as its use in determining ...

A patient with relapsed/refractory non-Hodgkin lymphoma received the first dose of a two-step radiotherapy using the ...

Minimally invasive screening methods offer a more accessible, cost-effective way to detect Barrett’s esophagus early and help prevent esophageal cancer.

Preclinical data has showing compelling findings for HT-KIT among patients with rare and aggressive KIT-driven cancers, ...

Radiation therapy can treat lung cancer at all stages, easing symptoms, improving precision and minimizing side effects with ...

A variant in the IL-7 gene may predict which patients with kidney cancer are more likely to experience side effects from immunotherapy.